Submit Deal

Announced

18 Nov 2024

Themis Medicare to acquire remaining 76.8% stake in Gujarat Themis Biosyn for $32m.

Synopsis

Themis Medicare, a manufacturer of therapeutic pharma products, differential healthcare products, APIs, agreed to acquire remaining 76.8% stake in Gujarat Themis Biosyn, a manufacturer and seller of finished active pharmaceutical ingredients products by fermentation process, for $32m.

Principals

target

Gujarat Themis Biosyn

bidder

Themis Medicare

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

tapas guha thakurata

CEO at GUJARAT THEMIS BIOSYN

Manager

target

Deal

£ 25 M

Total Value

Bidder Team (9)

aman yagnik

Counsel at Khaitan & Co

Lawyer

bidder

Deals

£ 9.93 B

Total Value

mansi kanodia

Associate at Khaitan & Co

Lawyer

bidder

Deal

£ 25 M

Total Value

sachin patel

CEO at THEMIS MEDICARE

Manager

bidder

Deal

£ 25 M

Total Value

mehul shah

Partner at Khaitan & Co

Lawyer

bidder

Deals

£ 12.91 B

Total Value

bhavin vora

Executive Director at Khaitan & Co

Lawyer

bidder

Deals

£ 1.25 B

Total Value

hiten kotak

Executive Director at Khaitan & Co

Lawyer

bidder

Deals

£ 1.11 B

Total Value

amit panwar

Senior Associate at Khaitan & Co

Lawyer

bidder

Deals

£ 8.71 B

Total Value

mohak shingala

Senior Associate at Khaitan & Co

Lawyer

bidder

Deals

£ 25 M

Total Value

anmol sharma

Associate at Khaitan & Co

Lawyer

bidder

Deal

£ 25 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy